Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Using Index Level to adjust risk lets you scale exposure in line with market momentum, maintaining a balanced, rules-based approach.
27,393 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Chewy has faced a rough year, with shares falling and growth challenges ahead. Yet, a closer look under the hood show...
A growing number of savers are adopting a three-bucket income strategy to generate roughly $60,000 a year from divide...
Investors piled into Nextpower after strong 2026 results and a strategic acquisition. This article breaks down the ca...
AI-related debt now accounts for about 15% of the debt corporate bond market, signaling a shift that could alter risk...
Mizuho ups UnitedHealth's price target to $440, citing easing medical loss ratio pressures and a turning Medicare Adv...
A synthetic covered‑call ETF on MicroStrategy stock continues to pay outs through monthly distributions, yet the stra...
Xactus has completed the acquisition of Mortgage Credit Link from MeridianLink, rebranding it as XedaLink and positio...
Crypto millionaire growth accelerates in 2026 as ETFs lure institutions and major tokens attract capital. Analysts we...
The UK regulator has issued a formal warning to soccer clubs about sponsorship deals with cryptocurrency firms. The m...
A niche shipping ETF has delivered extraordinary gains in 2026, turning a $100,000 investment into several million as...
Beyond Meat is shifting from plant-based meat to protein drinks. This article explores whether beyond meat's pivot pr...